Trace amines and their relevance to psychiatry and neurology: A brief overview;Eser aminler ve psikiyatri ve nöroloji ile ilişkisi: Kısa bir gözden geçirme

Klinik Psikofarmakoloji Bulteni

Volumn 21, Issue 1, 2011, Pages 73-79

  Narang, Deepak ^a   Tomlinson, Sara ^a   Holt, Andrew ^a   Mousseau, Darrell D ^b   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Octopamine; Psychiatric and neurological disorders; Trace amine associated receptors; Tryptamine; Tyramine; phenylethylamine

Indexed keywords

3 IODOTHYRONAMINE; AMINE; AMIODARONE; AMPHETAMINE; ANTIPARKINSON AGENT; ARALKYLAMINE; BROMOCRIPTINE; DIIODOTHYRONINE; DOPAMINE; G PROTEIN COUPLED RECEPTOR; LEVODOPA; LISURIDE; META TYRAMINE; METHAMPHETAMINE; NEUROTRANSMITTER; NORADRENALIN; NORFENEFRINE; OCTOPAMINE; OXEDRINE; PHENELZINE; PHENETHYLAMINE; PHENYLETHANOLAMINE; SEROTONIN; TRACE AMINE ASSOCIATED RECEPTOR; TRACE AMINE ASSOCIATED RECEPTOR 1 BLOCKING AGENT; TRACER AMINE; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG;

BIPOLAR DISORDER; CATECHOLAMINERGIC SYSTEM; CONCENTRATION (PARAMETERS); DISEASE MODEL; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; HEART ARRHYTHMIA; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROLOGY; NONHUMAN; PROTEIN LOCALIZATION; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SPECIES DIFFERENCE;

EID: 79955603799     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5350/kpb-bcp201121113     Document Type: Review

References (87)

1. Boulton AA, Baker GB, Dewhurst WG, Sandler M (editors). Neurobiology of the trace amines: analytical, physiological, pharmacological, behavioral, and clinical aspects. Clifton, N.J.: Humana Press; 1984.
2. Mosnaim AD, Wolf ME (editors). Noncatecholic phenylethylamines. New York: M. Dekker; 1978.
3. Boulton AA, Bieck PR, Maitre L, Riederer P (editors). Neuropsychopharmacology of the trace amines: experimental and clinical aspects. Clifton, N.J.: Humana Press; 1985.
4. Holt A, Todd KG, Baker GB. The effects of chronic administration of inhibitors of flavin and quinone amine oxidase on imidazoline I1 receoptor density in rat whole brain. Ann NY Acad Sci 2003; 1009:309-22.
5. Berry MD. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials 2007;2:3-19.
6. Boulton AA, Downer RGH, Juorio AV (editors). Trace amines: comparative and clinical neurobiology. Clifton, N.J.: Humana Press; 1988.
7. Baker GB, Bornstein RA, Yeragani VK. Trace amines and Tourette's syndrome. Neurochem Res 1993;18:951-6.
8. Tomlinson S, Baker GB. Trace Amines. In: Stolerman IP (editor). Encyclopedia of Psychopharmacology. Berlin: Springer; 2010.
9. Roeder T. Tyramine and octopamine: ruling behavior and metabolism. Annu Rev Entomol 2005;50:447-77.
10. Kellar KJ, Cascio CS. [3H]Tryptamine: high affinity binding sites in rat brain. Eur J Pharmacol 1982;78:475-8.
11. Hauger RL, Skolnick P, Paul SM. Specific [3H] beta-phenylethylamine binding sites in rat brain. Eur J Pharmacol 1982;83:147-8.
12. Wood PL, Pilapil C, LaFaille F, Nair NP, Glennon RA. Unique [3H] tryptamine binding sites in rat brain: distribution and pharmacology. Arch Int Pharmacodyn Ther 1984;268:194-201.
13. Vaccari A. High affinity binding of [3H]-tyramine in the central nervous system. Br J Pharmacol 1986;89:15-25.
14. Mousseau DD. Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders. Metab Brain Dis 1993;8:1-44.
15. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C. Trace amines: identification of a family of mammalian G protein- coupled receptors. Proc Natl Acad Sci U S A 2001;98:8966-71.
16. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001;60:1181-88.
17. Grandy DK. Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 2007;116:355-90.
18. Raiteri M, Del Carmine R, Bertollini A, Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 1977;41:133-43.
19. Jones RS. Tryptamine: a neuromodulator or neurotransmitter in mammalian brain? Prog Neurobiol 1982;19:117-39.
20. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990;55:1827-37.
21. Ishida K, Murata M, Kato M, Utsunomiya I, Hoshi K, Taguchi K. Beta-phenylethylamine stimulates striatal acetylcholine release through activation of the AMPA glutamatergic pathway. Biol Pharm Bull 2005;28:1626-9.
22. Berretta N, Giustizieri M, Bernardi G, Mercuri NB. Trace amines reduce GABA-B receptor-mediated presynaptic inhibition at GABAergic synapses of the rat substantia nigra pars compacta. Brain Research 2005;1062:175-78.
23. Federici M, Geracitano R, Tozzi A, Longone P, Di Angelantonio S, Bengtson CP, Bernardi G, Mercuri NB. Trace amines depress GABA-B response in dopaminergic neurons by inhibiting G-betagamma-gated inwardly rectifying potassium channels. Mol Pharmacol 2005;67:1283-90.
24. Boulton AA, Baker GB. The subcellular distribution of ß-phenylethylamine, p-tyramine and tryptamine in rat brain. J Neurochem 1975;25:477-81.
25. Juorio AV, Greenshaw AJ, Wishart TB. Reciprocal changes in striatal dopamine and ß-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors. Naunyn Schmiedeberg's Arch Pharmacol 1988;338:644-8.
26. Juorio AV, Greenshaw AJ, Nguyen TV. Effect of intranigral administration of 6-hydroxydopamine and 5,7-dihydroxytryptamine on rat brain tryptamine. J Neurochem 1987;48:1346-50.
27. Juorio AV, Jones RS. The effect of mesencephalic lesions on tyramine and dopamine in the caudate nucleus of the rat. J Neurochem 1981;36:1898-903.
28. Burchett SA, Hicks TP. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 2006;79:223-46.
29. Davis BA. Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects. J Chromatogr 1989;466:89-218.
30. Davis BA, Boulton AA. The trace amines and their acidic metabolites in depression--an overview. Prog Neuro-Psychopharmacol & Bio Psychiatry 1994;18:17-45.
31. DeLisi LE, Murphy DL, Karoum F, Mueller E, Targum S, Wyatt RJ. Phenylethylamine excretion in depression. Psychiatry Res 1984;13:193-201.
32. Sabelli HC, Mosnaim AD. Phenylethylamine hypothesis of affective behavior. Am J Psychiatry 1974;131:695-9.
33. Sandler M, Ruthven CR, Goodwin BL, Coppen A. Decreased cerebrospinal fluid concentration of free phenylacetic acid in depressive illness. Clin Chim Acta 1979;93:169-71.
34. Sandler, M. Bonham-Carter, SM, Walker, PL. Tyramine and depressive illness. In: Boulton, AA, Baker, GB, Dewhurst, WG and Sandler, M. (eds). Neurobiology of the Trace Amines. Clifton, NJ: Humana Press, 1984: 487-498.
35. Carter SB, Sandler M, Goodwin BL, Sepping P, Bridges PK. Decreased urinary output of tyramine and its metabolites in depression. Br J Psychiatry 1978;132:125-32.
36. O'Reilly RL, Davis BA. Phenylethylamine and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:63-75.
37. Potkin SG, Karoum F, Chuang LW, Cannon-Spoor HE, Phillips I, Wyatt RJ. Phenylethylamine in paranoid chronic schizophrenia. Science 1979;206:470-1.
38. Sullivan, JL, Coffey, CE, Basuk, B, Cavenar, JO, Maltbie, AA and Zung WW. Urinary tryptamine excretion in chronic schizophrneics with low platelet MAO activity. Biol Psychiatry 1980;15: 113-20.
39. Faraj BA, Newman SL, Caplan DB, Ali FM, Camp VM, Ahmann PA. Evidence for hypertyraminemia in Reye's syndrome. Pediatrics 1979;64:76-80.
40. Lloyd KG, Davidson L, Price K, McClung HJ, Gall DG. Catecholamine and octopamine concentrations in brains of patients with Reye syndrome. Neurology 1977;27:985-8.
41. Baker GB, Bornstein RA, Rouget AC, Ashton SE, van Muyden JC, Coutts RT. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 1991;29:15-22.
42. Borison RL, Mosnaim AD, Sabelli HC. Brain 2-phenylethylamine as a major mediator for the central actions of amphetamine and methylphenidate. Life Sci 1975;17:1331-43.
43. Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 2005;26:274-81.
44. Zametkin AJ, Karoum F, Rapoport JL, Brown GL, Wyatt RJ. Phenylethylamine excretion in attention deficit disorder. J Am Acad Child Psychiatry 1984;23:310-4.
45. Reynolds GP, Seakins JW, Gray DO. The urinary excretion of 2-phenylethylamine in phenylketonuria. Clin Chim Acta 1978;83:33-9.
46. Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. Gen Pharmacol 1983;14:385-90.
47. Oates JA, Nirenberg PZ, Jepson JB, Sjoerdsma A, Udenfriend S. Conversion of phenylalanine to phenethylamine in patients with phenylketonuria. Proc Soc Exp Biol Med 1963;112:1078-81.
48. D'Andrea G, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, Bussone G. Elevated levels of circulating trace amines in primary headaches. Neurology 2004;62:1701-05.
49. D'Andrea G, Granella F, Leone M, Perini F, Farruggio A, Bussone G. Abnormal platelet trace amine profiles in migraine with and without aura. Cephalalgia 2006;26:968-72.
50. Bakker SC, van der Meulen EM, Buitelaar JK, Sandkuijl LA, Pauls DL, Monsuur AJ, van 't Slot R, Minderaa RB, Gunning WB, Pearson PL, Sinke RJ. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003;72:1251-60.
51. Lapin IP. Beta-phenylethylamine (PEA): an endogenous anxiogen? Three series of experimental data. Biol Psychiatry 1990;28:997-1003.
52. Paulos MA, Tessel RE. Excretion of beta-phenethylamine is elevated in humans after profound stress. Science 1982;215:1127-9.
53. Dourish CT, Cooper SJ. Pharmacology of beta-phenylethylamine-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:787-90.
54. Baker GB. Chronic administration of monoamine oxidase inhibitors: Implications for interactions between trace amines and catecholamines. In: Dahlstrom, A. Belmaker RH, Sandler, M (editors).Progress in Catecholamine Research. Part A: Basic Aspects and Peripheral Mechanisms. New York, NY, Alan R. Liss, 1988.
55. Boulton AA, Juorio AV, Philips SR, Wu PH. The effects of reserpine and 6-hydroxydopamine on the concentrations of some arylakylamines in rat brain. Br J Pharmacol 1977;59:209-14.
56. Paetsch PR, Baker GB, Greenshaw AJ. Induction of functional down- regulation of beta-adrenoceptors in rats by 2-phenylethylamine. J Pharm Sci 1993;82:22-4.
57. Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise? Br J Sports Med 2001;35:342-3.
58. Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004;63:S32-5.
59. Juorio AV. Drug-induced changes in the central metabolism of tyramine an dother trace monoamines: Their possible role in brain functions. In: Boulton AA, Baker GB, Dewhurst WG, Sandler AD (editor). Nuerobiology of the Trace Amines. Edited by. Clifton, NJ: Humana Press; 1984.
60. Juorio AV, Greenshaw AJ, Zhu MY, Paterson IA. The effects of some neuroleptics and d-amphetamine on striatal 2-phenylethylamine in the mouse. Gen Pharmacol 1991;22:407-13.
61. Staubert C, Boselt I, Bohnekamp J, Rompler H, Enard W, Schoneberg T. Structural and functional evolution of the trace amine-associated receptors TAAR3, TAAR4 and TAAR5 in primates. PLoS One 2010;5:e11133.
62. Vallender EJ, Xie Z, Westmoreland SV, Miller GM. Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs. BMC Evol Biol 2010;10:51.
63. Xie Z, Vallender EJ, Yu N, Kirstein SL, Yang H, Bahn ME, Westmoreland SV, Miller GM. Cloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic association. J Neurosci Res 2008;86:3435-46.
64. Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005;85:372-85.
65. Middleton FA, Pato MT, Gentile KL, Morley CP, Zhao X, Eisener AF, Brown A, Petryshen TL, Kirby AN, Medeiros H, Carvalho C, Macedo A, Dourado A, Coelho I, Valente J, Soares MJ, Ferreira CP, Lei M, Azevedo MH, Kennedy JL, Daly MJ, Sklar P, Pato CN. Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22. Am J Hum Genet 2004;74:886-97.
66. Pato CN, Middleton FA, Gentile KL, Morley CP, Medeiros H, Macedo A, Azevedo MH, Pato MT. Genetic linkage of bipolar disorder to chromosome 6q22 is a consistent finding in Portuguese subpopulations and may generalize to broader populations. Am J Med Genet B Neuropsychiatr Genet 2005;134B:119-21.
67. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 2007;6:628-39.
68. Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, Lee C, Mandelli L, De Ronchi D, Paik IH, Serretti A. TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study. Eur Psychiatry 2008;23:390-5.
69. Pae CU, Drago A, Mandelli L, De Ronchi D, Serretti A. TAAR 6 and HSP-70 variations associated with bipolar disorder. Neurosci Lett 2009;465:257-61.
70. Pae CU, Yu HS, Amann D, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Patkar AA, Lerer B. Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. J Psychiatr Res 2008;42:35-40.
71. Ludewick HP, Schwab SG, Albus M, Lerer B, Maier W, Trixler M, Wildenauer DB. No support for an association with TAAR6 and schizophrenia in a linked population of European ancestry. Psychiatr Genet 2008;18:208-10.
72. Vladimirov VI, Maher BS, Wormley B, O'Neill FA, Walsh D, Kendler KS, Riley BP. The trace amine associated receptor (TAAR6) gene is not associated with schizophrenia in the Irish Case-Control Study of Schizophrenia (ICCSS) sample. Schizophr Res 2009;107:249-54.
73. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, Hoener MC. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 2008;324:948-56.
74. Sotnikova TD, Zorina OI, Ghisi V, Caron MG, Gainetdinov RR. Trace amine associated receptor 1 and movement control. Parkinsonism & Rel Dis 2008;14:S99-S102.
75. Ianculescu AG, Scanlan TS. 3-Iodothyronamine (T(1)AM): a new chapter of thyroid hormone endocrinology? Mol Biosyst 2010;6:1338-44.
76. Scanlan TS. Minireview: 3-Iodothyronamine (T1AM): a new player on the thyroid endocrine team? Endocrinology 2009;150:1108-11.
77. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004;10:638-42.
78. Frascarelli S, Ghelardoni S, Chiellini G, Vargiu R, Ronca-Testoni S, Scanlan TS, Grandy DK, Zucchi R. Cardiac effects of trace amines: pharmacological characterization of trace amine-associated receptors. Eur J Pharmacol 2008;587:231-36.
79. Tan ES, Miyakawa M, Bunzow JR, Grandy DK, Scanlan TS. Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1. J Med Chem 2007;50:2787-98.
80. Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, Scanlan TS, Miller GM. Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J Neurosci Res 2010;88:1962-9.
81. Snead AN, Miyakawa M, Tan ES, Scanlan TS. Trace amine- associated receptor 1 (TAAR1) is activated by amiodarone metabolites. Bioorg Med Chem Lett 2008;18:5920-2.
82. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol and Exp Ther 2007;321:178-86.
83. Xie Z, Miller GM. A Receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther 2009;330:316-25.
84. Xie Z, Miller GM. Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem Pharmacol 2009;78:1095-104.
85. Xie Z, Miller GM. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 2007;321:128-36.
86. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 2003;27:552-9.
87. McClung C, Hirsh J. The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr Biol 1999;9:853-60.